Welcome to our dedicated page for Resmed news (Ticker: RMD), a resource for investors and traders seeking the latest updates and insights on Resmed stock.
ResMed Inc. (RMD) is a health technology company focused on sleep, breathing, and care delivered in the home, and its news flow reflects that focus. Company announcements regularly describe how ResMed creates life-changing health technologies, combining AI-powered digital health solutions, cloud-connected devices, and intelligent software to support sleep and breathing therapy for people in more than 140 countries.
Investors following RMD news can expect updates on financial performance and capital returns, including quarterly earnings releases, dividend declarations, and details of investor webcasts. ResMed frequently issues press releases about its results of operations, margins, cash flow, and related board decisions such as quarterly cash dividends, as documented in its Form 8-K filings and Globe Newswire announcements.
ResMed’s news also highlights product and technology developments. Recent communications include FDA clearance for Smart Comfort, an AI-enabled digital medical device that recommends personalized comfort settings for CPAP therapy, and design awards for the AirTouch N30i nasal cradle mask. These stories often emphasize the use of real-world sleep data, machine learning, and human-centered design to improve comfort and adherence for people with obstructive sleep apnea.
Another recurring theme in ResMed’s news is research and clinical insights. The company has announced landmark studies in The Lancet Respiratory Medicine projecting future obstructive sleep apnea prevalence, as well as meta-analyses on CPAP therapy and mortality. It has also launched initiatives like Sleep Institute to publish evidence-based insights that inform care models and policy discussions around sleep health.
Corporate governance and investor-relations events appear frequently in RMD news as well, including participation in major healthcare conferences, updates on board composition, and details of annual meetings. For readers and investors, the RMD news page offers a centralized view of ResMed’s earnings, product clearances, research publications, and strategic initiatives related to sleep and breathing health.
ResMed has appointed Urvashi Tyagi as its new Chief Technology Officer effective February 1, 2022. With over 25 years of experience from companies like ADP, American Express, and Amazon, Tyagi will spearhead ResMed's digital health innovation and cloud technologies. Bobby Ghoshal, the former CTO, will now focus entirely on leading the company’s SaaS business. CEO Mick Farrell emphasized Tyagi's leadership skills and experience as pivotal for enhancing ResMed's digital ecosystem aimed at improving the lives of 250 million people by 2025.
ResMed (NYSE: RMD) reported a 12% year-over-year revenue increase, reaching $894.9 million for Q2 2022. Operating profit also rose by 12%, while non-GAAP operating profit saw a 5% growth. Diluted earnings per share climbed to $1.37, and non-GAAP diluted earnings per share hit $1.47. Despite challenges in supply chains, ResMed managed to meet high demand for sleep and respiratory care products. The company announces a quarterly cash dividend of $0.42 per share, payable on March 17, 2022, and continues its goal to improve life quality for 250 million people by 2025.
ResMed (NYSE: RMD) announced it will release its financial and operational results for Q2 fiscal year 2022 on January 27, 2022, post-market. This will be followed by a management webcast to discuss the results and other relevant information. Key details include the earnings call scheduled at 1:30 p.m. PST / 4:30 p.m. EST, with international times listed for London and Sydney. A replay of the webcast will be available approximately two hours after the event.
ResMed (NYSE: RMD) announced that CEO Mick Farrell will present at the 40th Annual J.P. Morgan Healthcare Conference on January 10, 2022, at 1:30 p.m. EST via webcast. This conference offers an opportunity for investors to hear about ResMed’s innovative solutions for chronic diseases and its digital health technologies. Access to the live webcast and the replay will be available through their investor relations website. The presentation aims to highlight how ResMed is improving healthcare quality and reducing costs globally.
ResMed (NYSE: RMD) announced that CEO Mick Farrell will present at the Goldman Sachs 14th Annual Healthcare CEOs Unscripted Conference on January 6, 2022, at 4:00 p.m. EST. The event will be available via live webcast, with a replay accessible for one year after the event. ResMed focuses on innovative healthcare solutions that treat chronic diseases, enhancing quality of life and reducing healthcare costs across more than 140 countries.
ResMed has appointed Desney Tan and John Hernandez to its board of directors, increasing the board from eight to ten members. Tan, current vice president at Microsoft, brings expertise in AI and health R&D, while Hernandez leads clinical research at Google. Their backgrounds in digital health aim to enhance ResMed's strategy of improving 250 million lives by 2025. This strategic move is part of ResMed's commitment to advancements in digital health and health economics.
ResMed (NYSE: RMD) announced that CEO Mick Farrell will participate in a virtual fireside chat at the Credit Suisse 30th Annual Healthcare Conference on November 10, 2021, at approximately 1:00 p.m. EST. The event will be accessible via video webcast, with a replay available 24 hours post-event until February 8, 2021. ResMed focuses on innovative healthcare solutions, particularly in digital health technologies and cloud-connected medical devices for chronic diseases.
ResMed reported a 20% increase in revenue to $904.0 million for Q1 fiscal 2022, with operating profit up 21%. Non-GAAP operating profit rose 18%, and diluted EPS reached $1.39. Despite COVID-19 related demand fluctuations impacting ventilator sales, the growth was fueled by strong demand for sleep and respiratory products, alongside a recent competitor recall. However, gross margins contracted due to rising costs. The company settled a significant tax dispute, impacting cash flow but providing clarity for future operations.
ResMed (NYSE: RMD) has announced the release of its financial and operational results for Q1 FY2022 on October 28, 2021, after market closing. Management will host a webcast to discuss these results and potentially other forward-looking information. The event is scheduled for 1:30 PM PDT / 4:30 PM EDT. A replay of the webcast will be available on ResMed's website. As a leading innovator in healthcare technology for chronic diseases, ResMed aims to enhance patient care and reduce healthcare costs.
ResMed (NYSE: RMD) announced that Rob Douglas, the president and COO, will speak at the Bank of America Global Healthcare Conference on September 15, 2021, at approximately 5:35 p.m. BST. The event will be held virtually and can be accessed via video webcast. A replay of the webcast will be available one hour after the event and accessible until December 16, 2021. ResMed is noted for pioneering digital health technologies and cloud-connected devices aimed at improving care for chronic disease patients globally.